vs

Side-by-side financial comparison of CLOVER HEALTH INVESTMENTS, CORP. (CLOV) and BOSTON BEER CO INC (SAM). Click either name above to swap in a different company.

CLOVER HEALTH INVESTMENTS, CORP. is the larger business by last-quarter revenue ($487.7M vs $461.6M, roughly 1.1× BOSTON BEER CO INC). On growth, CLOVER HEALTH INVESTMENTS, CORP. posted the faster year-over-year revenue change (44.7% vs -4.1%). Over the past eight quarters, CLOVER HEALTH INVESTMENTS, CORP.'s revenue compounded faster (18.6% CAGR vs -10.7%).

Clover Health Investments, Corp. is an American health care company founded in 2014. The company provides Medicare Advantage (MA) insurance plans and operates as a direct contracting entity with the U.S. government. The company manages care for Medicare beneficiaries in 11 states and started trading publicly on January 8, 2021.

The Boston Beer Company is an American brewery founded in 1984 by James "Jim" Koch and Rhonda Kallman. Boston Beer Company's first brand of beer was named Samuel Adams after Founding Father Samuel Adams, an American revolutionary patriot. Since its founding, Boston Beer has started several other brands, and in 2019 completed a merger with Dogfish Head Brewery.

CLOV vs SAM — Head-to-Head

Bigger by revenue
CLOV
CLOV
1.1× larger
CLOV
$487.7M
$461.6M
SAM
Growing faster (revenue YoY)
CLOV
CLOV
+48.8% gap
CLOV
44.7%
-4.1%
SAM
Faster 2-yr revenue CAGR
CLOV
CLOV
Annualised
CLOV
18.6%
-10.7%
SAM

Income Statement — Q4 FY2025 vs Q1 FY2026

Metric
CLOV
CLOV
SAM
SAM
Revenue
$487.7M
$461.6M
Net Profit
$-49.3M
Gross Margin
46.4%
Operating Margin
-10.1%
12.4%
Net Margin
-10.1%
Revenue YoY
44.7%
-4.1%
Net Profit YoY
-123.2%
EPS (diluted)
$2.16

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
CLOV
CLOV
SAM
SAM
Q1 26
$461.6M
Q4 25
$487.7M
$385.7M
Q3 25
$496.6M
$537.5M
Q2 25
$477.6M
$587.9M
Q1 25
$462.3M
$453.9M
Q4 24
$337.0M
$402.3M
Q3 24
$331.0M
$605.5M
Q2 24
$356.3M
$579.1M
Net Profit
CLOV
CLOV
SAM
SAM
Q1 26
Q4 25
$-49.3M
$-22.5M
Q3 25
$-24.4M
$46.2M
Q2 25
$-10.6M
$60.4M
Q1 25
$-1.3M
$24.4M
Q4 24
$-22.1M
$-38.8M
Q3 24
$-9.2M
$33.5M
Q2 24
$7.4M
$52.3M
Gross Margin
CLOV
CLOV
SAM
SAM
Q1 26
46.4%
Q4 25
43.5%
Q3 25
50.8%
Q2 25
49.8%
Q1 25
48.3%
Q4 24
39.9%
Q3 24
24.5%
46.3%
Q2 24
30.3%
46.0%
Operating Margin
CLOV
CLOV
SAM
SAM
Q1 26
12.4%
Q4 25
-10.1%
-8.6%
Q3 25
-4.9%
11.5%
Q2 25
-2.2%
14.0%
Q1 25
-0.3%
7.4%
Q4 24
-6.4%
-13.9%
Q3 24
-2.7%
7.6%
Q2 24
2.0%
12.2%
Net Margin
CLOV
CLOV
SAM
SAM
Q1 26
Q4 25
-10.1%
-5.8%
Q3 25
-4.9%
8.6%
Q2 25
-2.2%
10.3%
Q1 25
-0.3%
5.4%
Q4 24
-6.6%
-9.6%
Q3 24
-2.8%
5.5%
Q2 24
2.1%
9.0%
EPS (diluted)
CLOV
CLOV
SAM
SAM
Q1 26
$2.16
Q4 25
$-1.97
Q3 25
$4.25
Q2 25
$5.45
Q1 25
$2.16
Q4 24
$-3.23
Q3 24
$2.86
Q2 24
$4.39

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
CLOV
CLOV
SAM
SAM
Cash + ST InvestmentsLiquidity on hand
$78.3M
$164.1M
Total DebtLower is stronger
Stockholders' EquityBook value
$308.7M
$682.6M
Total Assets
$541.0M
$1.2B
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
CLOV
CLOV
SAM
SAM
Q1 26
$164.1M
Q4 25
$78.3M
$223.4M
Q3 25
$250.5M
Q2 25
$212.4M
Q1 25
$152.5M
Q4 24
$194.5M
$211.8M
Q3 24
$288.0M
$255.6M
Q2 24
$254.8M
$219.3M
Stockholders' Equity
CLOV
CLOV
SAM
SAM
Q1 26
$682.6M
Q4 25
$308.7M
$846.3M
Q3 25
$340.9M
$911.0M
Q2 25
$344.2M
$912.3M
Q1 25
$336.1M
$897.0M
Q4 24
$341.1M
$916.2M
Q3 24
$342.2M
$1.0B
Q2 24
$324.9M
$1.0B
Total Assets
CLOV
CLOV
SAM
SAM
Q1 26
$1.2B
Q4 25
$541.0M
$1.2B
Q3 25
$559.7M
$1.2B
Q2 25
$575.0M
$1.3B
Q1 25
$583.7M
$1.2B
Q4 24
$580.7M
$1.3B
Q3 24
$653.0M
$1.4B
Q2 24
$674.2M
$1.4B

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
CLOV
CLOV
SAM
SAM
Operating Cash FlowLast quarter
$-66.9M
Free Cash FlowOCF − Capex
$-69.0M
FCF MarginFCF / Revenue
-14.1%
Capex IntensityCapex / Revenue
0.4%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-69.2M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
CLOV
CLOV
SAM
SAM
Q1 26
Q4 25
$-66.9M
$39.9M
Q3 25
$12.1M
$101.8M
Q2 25
$5.4M
$126.5M
Q1 25
$-16.3M
$1.9M
Q4 24
$34.8M
$41.9M
Q3 24
$50.0M
$115.9M
Q2 24
$44.8M
$96.0M
Free Cash Flow
CLOV
CLOV
SAM
SAM
Q1 26
Q4 25
$-69.0M
$22.1M
Q3 25
$11.4M
$89.2M
Q2 25
$4.8M
$112.2M
Q1 25
$-16.5M
$-8.0M
Q4 24
$33.3M
$18.4M
Q3 24
$49.6M
$99.2M
Q2 24
$44.4M
$75.6M
FCF Margin
CLOV
CLOV
SAM
SAM
Q1 26
Q4 25
-14.1%
5.7%
Q3 25
2.3%
16.6%
Q2 25
1.0%
19.1%
Q1 25
-3.6%
-1.8%
Q4 24
9.9%
4.6%
Q3 24
15.0%
16.4%
Q2 24
12.5%
13.1%
Capex Intensity
CLOV
CLOV
SAM
SAM
Q1 26
Q4 25
0.4%
4.6%
Q3 25
0.1%
2.3%
Q2 25
0.1%
2.4%
Q1 25
0.0%
2.2%
Q4 24
0.5%
5.8%
Q3 24
0.1%
2.8%
Q2 24
0.1%
3.5%
Cash Conversion
CLOV
CLOV
SAM
SAM
Q1 26
Q4 25
Q3 25
2.21×
Q2 25
2.09×
Q1 25
0.08×
Q4 24
Q3 24
3.46×
Q2 24
6.04×
1.83×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons